



International
Federation of
Pharmaceutical
Manufacturers &
Associations

Fédération
Internationale de
l'Industrie du
Médicament

Federación
Internacional de la
Industria del
Medicamento



News Release

Mr. David Brennan of AstraZeneca Elected President of IFPMA

New Vice Presidents are Mr. John Lechleiter of Lilly and Mr. Masafumi Nogimori of Astellas

Washington DC, 10 November 2010 –The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) is pleased to announce that Mr. David Brennan, Chief Executive Officer of AstraZeneca has been elected IFPMA President. Mr. Brennan succeeds outgoing IFPMA President Mr. Haruo Naito, President and CEO of Eisai Co., Ltd. Mr. John Lechleiter, who is Chairman, President and CEO of Eli Lilly and Company, and Mr. Masafumi Nogimori, President and CEO of Astellas Pharma Inc., have been elected as Vice Presidents. The new President and Vice Presidents take office today and will serve for two years.

Mr. Brennan outlined his objectives for his term as President, which include building on existing IFPMA efforts to engage openly with partners in addressing pressing global health challenges, including non-communicable diseases, diseases of the developing world and anti-microbial resistance.

Mr. Brennan said, “I would like to pay tribute to Mr. Naito, for the energy and commitment he has brought to his Presidency. As the first Japanese President of the IFPMA, he has brought a new perspective to our work and underlined the increasing globalization of our industry. Mr. Naito has led from the front, personally helping to develop and strengthen relationships with key external partners, particularly in Geneva and I want to build on the success of his Presidency.”

“Looking to the future, our industry needs to rebuild trust and do a better job of showing the public that we play a crucial role in addressing healthcare challenges, in all parts of the world. Increasing the levels of transparency is one of the best ways to build relationships and understanding, and I will help the IFPMA to continue its work in this area.”

“If there is a theme I want to underline during my presidency, it is that of the ‘shared commitment’. It is the sharing of the challenge that is so important.” Mr. Brennan concluded: “It is the collaborative effort that will really make the difference.”

(ends)

About David Brennan:

From 2001 until his appointment to CEO of AstraZeneca, David Brennan was President and Chief Executive Officer of AstraZeneca LP, the Company's North America subsidiary. He was appointed Executive Board Director of AstraZeneca in 2005, with responsibility for the United States, the company's largest market, as well as all North American operations.

David began his career in 1975 at Merck, where he rose from sales representative in the U.S. Division to general manager of Chibret International, a French subsidiary of Merck specializing in ophthalmics. He joined AstraMerck in 1992 with responsibility for helping to build the joint venture into a multi-billion dollar business in the U.S. Prior to the AstraZeneca merger he was responsible for business planning and development at Astra Pharmaceuticals. He was appointed Senior Vice-President of Commercial Operations of AstraZeneca Pharmaceuticals LP in 1999. He is an alumnus of Gettysburg College.

David is an Executive Director of AstraZeneca PLC. He is a Chairman of the Executive Board of the Pharmaceutical Research and Manufacturers of America (PhRMA) and a Member of the Executive Board of the European Federation of Pharmaceutical Industries and Associations (EFPIA). In addition, he is past Chairman of the Board of the Southeastern Pennsylvania Chapter of the American Heart Association, and Honorary Board member of the US CEO Roundtable on Cancer. In December 2007, David was appointed a Commissioner of the UK Commission for Employment and Skills.

About the IFPMA:

The International Federation of Pharmaceutical Manufacturers & Associations is the global non-profit NGO representing the research-based pharmaceutical industry, including the biotech and vaccine sectors. Its members comprise 26 leading international companies and 46 national and regional industry associations covering developed and developing countries. The industry's R&D pipeline contains hundreds of new medicines and vaccines being developed to address global disease threats, including cancer, heart disease, HIV/AIDS and malaria. The IFPMA Clinical Trials Portal (www.ifpma.org/ClinicalTrials), the IFPMA's Ethical Promotion online resource (www.ifpma.org/EthicalPromotion/) and its Developing World Health Partnerships Directory (www.ifpma.org/HealthPartnerships) help make the industry's activities more transparent. The IFPMA supports a wide range of WHO technical activities, notably those relating to medicine efficacy, quality and safety, and coordinates industry participation in the WHO IMPACT initiative to combat counterfeit medicines. It also provides the secretariat for the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH).

For further information, please contact:

Guy Willis
Director of Communications
E-mail: g.willis@ifpma.org
Tel: +41 22 338 32 00
Fax: +41 22 338 32 99
Web: www.ifpma.org